Venous thrombosis after traumatic injury
Active Project Grant Awarded Last action
- Award ID
- R01HL162729
- Recipient
-
Mayo Clinic UEI Y2K4F9RPRRG7 Part of Mayo Clinic
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,319,356
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 81% complete
- Place of performance
- Rochester, MN 55905, USA
Award details come from USAspending.gov.
Description
- Abstract
- Venous thromboembolism (VTE) continues to be a major health problem with over 500,000 VTE events in the US annually. Venous thromboembolism costs more than $8 billion per year to our health care system and causes more than 100,000 deaths per year in the US alone. Venous thromboembolism is particularly problematic in patients who experience trauma. Despite administration of chemoprophylaxis to trauma patients during hospitalization, about 5% of patients still develop symptomatic VTE prior to discharge, and, more alarmingly, 40 - 60% of patients who develop symptomatic VTE, do so after discharge. An accurate assessment of traumatic- injury based coagulopathies remains dependent on unavailable basic scientific knowledge needed to address the national institutes of health (NIH) initiative of defining the "role of laboratory monitoring…to help better define those at risk of bleeding and thrombosis." to understand the etiologies of trauma-induced venous thromboembolism, a comprehensive approach that assesses plasma coagulation factor activities, platelet reactivity, and endothelial function within the context of pre-trauma patient characteristics (SEX, BMI, smoking etc.) and "real-time" blood studies at the time of trauma is required". Obtaining integrated lab and clinical data from a diverse trauma patient population is not readily feasible in a single investigator's laboratory or site. The long-term goal is to develop novel predictive, diagnostic and treatment strategies that identify "at risk" individuals for VTE or bleeding soon after trauma. Our central hypothesis is that clinically significant thrombosis requires the integrated dysregulation of netosis, thrombin generation, endothelial injury, and VON willebrand factor- platelet dysfunction. Our collaboration embodies all of the elements needed to improve the quality of care of trauma patients. The investigators are from multiple health-related professions and this leverages experiences and knowledge from different, but related disciplines. Our collaboration also encourages and fosters scientific inquiry with the scientific expertise that will create and disseminate new knowledge and applications. Finally, the team science approach that we have culminated is expected to provide for the highest quality of care and improvement of trauma health outcomes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $644,193 | |
| Amendment | $656,905 | |
| Amendment | $648,296 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $684,981 | |
| Original award | $684,981 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Bloodworks | $76,000 | |
| University Of Maryland, Baltimore | $110,000 | |
| University Of Maryland, Baltimore | $136,476 | |
| Bloodworks | $96,336 | |
| University Of Maryland, Baltimore | $17,881 | |
| Bloodworks | $31,510 |
Quick answers
Who received award R01HL162729?
R01HL162729 was awarded to Mayo Clinic by National Heart Lung and Blood Institute (National Institutes of Health) on August 15, 2023.
How much is award R01HL162729 worth?
$3,319,356 has been obligated on R01HL162729.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award